Molecular mechanism of the interaction between activated factor XIII and its glutamine donor peptide substrate

Journal of Thrombosis and Haemostasis

Volumn 7, Issue 4, 2009, Pages 627-633

  Penzes K ^a   Kover K E ^b   Fazakas, F ^b   Haramura, G ^a   Muszbek, László ^a,b  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

A2 plasmin inhibitor; Factor XIII; Factor XIII substrate peptides; STD NMR; Transglutaminase

Indexed keywords

ALANINE; AMINO ACID; ASPARAGINE; BLOOD CLOTTING FACTOR 8; FIBRIN; GLUTAMINE; LEUCINE; PEPTIDE DERIVATIVE;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; ENZYME SUBSTRATE; FIBRINOLYSIS; HYDROPHOBICITY; KINETICS; MOLECULAR MECHANICS; MUTANT; MUTATION; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTON NUCLEAR MAGNETIC RESONANCE; TANDEM MASS SPECTROMETRY;

AMINO ACID SEQUENCE; ANIMALS; ASPARAGINE; BINDING SITES; CATTLE; FACTOR XIIIA; GLUTAMINE; HUMANS; HYDROPHOBICITY; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; MUTATION; PEPTIDES; PROTEIN BINDING; SUBSTRATE SPECIFICITY;

EID: 63049121121     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2009.03291.x     Document Type: Article

References (35)

1. Muszbek L, Yee VC, Hevessy Z. Blood coagulation factor XIII: Structure and function. Thromb Res 1999; 94: 271-305.
2. Muszbek L, Bagoly Z, Bereczky Z, Katona É. The involvement of blood coagulation factor XIII in fibrinolysis and thrombosis. Cardiovasc Hematol Agents Med Chem 2008; 6: 190-205.
3. Siebenlist KR, Meh D, Mosesson MW. Protransglutaminase (factor XIII) mediated cross linking of fibrinogen and fibrin. Thromb Haemost 2001; 86: 1221-8.
4. Mosesson MW, Siebenlist KR, Hernandez I, Lee KN, Christiansen VJ, McKee PA. Evidence that γ2-antiplasmin becomes covalently ligated to plasma fibrinogen in the circulation: A new role for plasma factor XIII in fibrinolysis regulation. J Thromb Haemost 2008; 6: 1565-70.
5. Koyama T, Koike Y, Toyota S, Miyagi F, Suzuki N, Aoki N. Different NH2-terminal form with 12 additional residues of alpha 2-plasmin inhibitor from human plasma and culture media of Hep G2 cells. Biochem Biophys Res Commun 1994; 200: 417-22.
6. Lee KN, Jackson KW, Christiansen VJ, Chung KH, McKee PA. A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion. Blood 2004; 103: 3783-8.
7. Sumi Y, Ichikawa Y, Nakamura Y, Miura O, Aoki N. Expression and characterization of pro alpha 2-plasmin inhibitor. J Biochem 1989; 106: 703-7.
8. Bangert K, Johnsen AH, Christensen U, Thorsen S. Different N-terminal forms of alpha 2-plasmin inhibitor in human plasma. Biochem J 1993; 291: 623-5.
9. Kimura S, Aoki N. Cross-linking site in fibrinogen for alpha 2-plasmin inhibitor. J Biol Chem 1986; 261: 15591-5.
10. Gorman JJ, Folk JE. Structural features of glutamine substrates for human plasma factor XIIIa (activated blood coagulation factor XIII). J Biol Chem 1980; 255: 419-27.
11. Fickenscher K, Aab A, Stüber W. A photometric assay for blood coagulation factor XIII. Thromb Haemost 1991; 65: 535-40.
12. Chen R, Doolittle RF. Y-Y cross-linking sites in human and bovine fibrin. Biochemistry 1971; 10: 4486-91.
13. Matsuka Y, Medved L, Migliorini M, Inghan K. Factor XIIIa-catalyzed cross-linking of recombinant alpha C fragments of human fibrinogen. Biochemistry 1996; 35: 5810-16.
14. Cotrell BA, Strong DD, Watt KWK, Doolittle RF. Amino acid sequence studies on the alpha chain of human fibrinogen. Exact location of cross-linking acceptor sites. Biochemistry 1979; 18: 5405-10.
15. McDonagh RP, McDonagh J, Peterson TE, Throrgersen HC, Skorstengaard K, Sottrup-Jensen L, Magnusson S, Dell A, Morris HR. Amino acid sequence of the factor XIIIa acceptor site in bovine plasma fibronectin. FEBS Lett 1981; 127: 174-8.
16. Skorstengaard K, Halkier T, Hojrup P, Mosher DF. Sequence location of a putative transglutaminase cross-linking site in human vitronectin. FEBS Lett 1990; 262: 269-74.
17. Valnickova Z, Enghild JJ. Human procarboxypeptidase. U, or thrombin-activable fibrinolysis inhibitor, is a substrate for transglutaminases. Evidence for transglutaminase-catalyzed cross-linking to fibrin. J Biol Chem 1998; 273: 27220-4.
18. Anderson ET, Fletcher L, Severin A, Murphy E, Baker SM, Matsuka YV. Identification of factor XIIIA-reactive glutamine acceptor and lysine donor sites within fibronectin-binding protein (FnbA) from Staphylococcus aureus. Biochemistry 2004; 43: 11842-52.
19. Gorman JJ, Folk JE. Structural features of glutamine substrates for transglutaminases. Role of extended interactions in the specificity of human plasma factor XIIIa and of the guinea pig liver enzyme. J Biol Chem 1984; 259: 9007-10.
20. Marinescu A, Cleary DB, Littlefield TR, Maurer MC. Structural features associated with the binding of glutamine-containing peptides to factor XIII. Arch Biochem Biophys 2002; 406: 9-20.
21. Cleary DB, Maurer MC. Characterizing the specificity of activated factor.XIII for glutamine-containing substrate peptides. Biochim Biophys Acta 2006; 1764: 1207-17.
22. Lorand L, Credo RB, Janus TJ. Factor XIII (fibrin-stabilizing factor). Methods Enzymol 1981; 80: 333-41.
23. Bajaj SP, Mann KG. Simultaneous purification of bovine prothrombin and factor X. Activation of prothrombin by trypsin-activated factor X. J Biol Chem 1973; 248: 7729-41.
24. Workman EF Jr, Lundblad RL. On the preparation of bovine alpha-thrombin. Thromb Haemost 1978; 39: 193-200.
25. Merrifield B. Solid phase synthesis. Science 1986; 232: 341-7.
26. Kárpáti L, Penke B, Katona É, Balogh I, Vámosi G, Muszbek L. A modified, optimized kinetic photometric assay for the determination of blood coagulation factor XIII activity in plasma. Clin Chem 2000; 46: 1946-55.
27. Fulton DB, Ni F. ROESY with water flip back for high-field NMR of biomolecules. J Magn Reson 1997; 129: 93-7.
28. Mayer M, Meyer B. Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor. J Am Chem Soc 2001; 123: 6108-17.
29. Wüthrich K. NMR of Proteins and Nucleic Acids. New York: Wiley, 1986.
30. Sakata Y, Aoki N. Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis. J Clin Invest 1982; 69: 536-42.
31. Tamaki T, Aoki N. Cross-linking of alpha 2-plasmin inhibitor to fibrin catalyzed by activated fibrin-stabilizing factor. J Biol Chem 1982; 257: 14767-72.
32. Lee KN, Lee CS, Tae WC, Jackson KW, Christiansen VJ, McKee PA. Cross-linking of wild-type and mutant alpha 2-antiplasmins to fibrin by activated factor XIII and by a tissue transglutaminase. J Biol Chem 2000; 275: 37382-9.
33. Holmes WE, Lijnen HR, Collen D. Characterization of recombinant human alpha 2-antiplasmin and of mutants obtained by site-directed mutagenesis of the reactive site. Biochemistry 1987; 26: 5133-40.
34. Ichinose A, Tamaki T, Aoki N. Factor XIII-mediated cross-linking of NH2-terminal peptide of alpha 2-plasmin inhibitor to fibrin. FEBS Lett 1983; 153: 369-71.
35. Sugimura Y, Hosono M, Wada F, Yoshimura T, Maki M, Hitomi K. Screening for the preferred substrate sequence of transglutaminase using a phage-displayed peptide library: Identification of peptide substrates for TGASE 2 and factor XIIIA. J Biol Chem 2006; 281: 17699-706.